PMID- 25828520
OWN - NLM
STAT- MEDLINE
DCOM- 20151231
LR  - 20211203
IS  - 1944-7930 (Electronic)
IS  - 1539-6509 (Linking)
VI  - 19
IP  - 104
DP  - 2015 Mar
TI  - Dendritic-tumor fusion cells in cancer immunotherapy.
PG  - 169-74
AB  - A promising area of clinical investigation is the use of cancer immunotherapy to 
      treat cancer patients. Dendritic cells (DCs) operate as professional 
      antigen-presenting cells (APCs) and play a critical role in the induction of 
      antitumor immune responses. Thus, DC-based cancer immunotherapy represents a 
      powerful strategy. One DC-based cancer immunotherapy strategy that has been 
      investigated is the administration of fusion cells generated with DCs and whole 
      tumor cells (DC-tumor fusion cells). The DC-tumor fusion cells can process a 
      broad array of tumor-associated antigens (TAAs), including unidentified 
      molecules, and present them through major histocompatibility complex (MHC) class 
      I and II pathways in the context of co-stimulatory signals. Improving the 
      therapeutic efficacy of DC-tumor fusion cell-based cancer immunotherapy requires 
      increased immunogenicity of DCs and whole tumor cells. We discuss the potential 
      ability of DC-tumor fusion cells to activate antigen-specific T cells and 
      strategies to improve the immunogenicity of DC-tumor fusion cells as anticancer 
      vaccines.
FAU - Takakura, Kazuki
AU  - Takakura K
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Kajihara, Mikio
AU  - Kajihara M
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Ito, Zensho
AU  - Ito Z
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, The 
      Jikei University School of Medicine, Tokyo, Japan.
FAU - Ohkusa, Toshifumi
AU  - Ohkusa T
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine; and 
      Institute of Clinical Medicine and Research; The Jikei University School of 
      Medicine, Tokyo, Japan.
FAU - Gong, Jianlin
AU  - Gong J
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Boston University School of Medicine, Boston, MA 02118, USA.
FAU - Koido, Shigeo
AU  - Koido S
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine; and 
      Institute of Clinical Medicine and Research; The Jikei University School of 
      Medicine, Tokyo, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Discov Med
JT  - Discovery medicine
JID - 101250006
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (TLR2 protein, human)
RN  - 0 (TLR4 protein, human)
RN  - 0 (Toll-Like Receptor 2)
RN  - 0 (Toll-Like Receptor 4)
RN  - 3K9958V90M (Ethanol)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/therapeutic use
MH  - Cell Fusion
MH  - Cell Line, Tumor
MH  - Dendritic Cells/*cytology
MH  - Ethanol/chemistry
MH  - Humans
MH  - Immunosuppression Therapy
MH  - Immunotherapy/*methods
MH  - Major Histocompatibility Complex
MH  - Neoplasms/*immunology/*pathology
MH  - T-Lymphocytes/immunology
MH  - Toll-Like Receptor 2/chemistry
MH  - Toll-Like Receptor 4/chemistry
EDAT- 2015/04/02 06:00
MHDA- 2016/01/01 06:00
CRDT- 2015/04/02 06:00
PHST- 2015/04/02 06:00 [entrez]
PHST- 2015/04/02 06:00 [pubmed]
PHST- 2016/01/01 06:00 [medline]
PST - ppublish
SO  - Discov Med. 2015 Mar;19(104):169-74.